Literature DB >> 24155399

Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo.

Mohamed Abdel-Mohsen1, Xutao Deng, Teri Liegler, John C Guatelli, Mohamed S Salama, Hussam El-din A Ghanem, Andri Rauch, Bruno Ledergerber, Steven G Deeks, Huldrych F Günthard, Joseph K Wong, Satish K Pillai.   

Abstract

Alpha interferon (IFN-α) suppresses human immunodeficiency virus type 1 (HIV-1) replication in vitro by inducing cell-intrinsic retroviral restriction mechanisms. We investigated the effects of IFN-α/ribavirin (IFN-α/riba) treatment on 34 anti-HIV-1 restriction factors in vivo. Expression of several anti-HIV-1 restriction factors was significantly induced by IFN-α/riba in HIV/hepatitis C virus (HCV)-coinfected individuals. Fold induction of cumulative restriction factor expression in CD4(+) T cells was significantly correlated with viral load reduction during IFN-α/riba treatment (r(2) = 0.649; P < 0.016). Exogenous IFN-α induces supraphysiologic restriction factor expression associated with a pronounced decrease in HIV-1 viremia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24155399      PMCID: PMC3911728          DOI: 10.1128/JVI.02687-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

Review 2.  Type I interferons in host defense.

Authors:  Daniel B Stetson; Ruslan Medzhitov
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

3.  Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Authors:  Satish K Pillai; Mohamed Abdel-Mohsen; John Guatelli; Mark Skasko; Alexander Monto; Katsuya Fujimoto; Steven Yukl; Warner C Greene; Helen Kovari; Andri Rauch; Jacques Fellay; Manuel Battegay; Bernard Hirschel; Andrea Witteck; Enos Bernasconi; Bruno Ledergerber; Huldrych F Günthard; Joseph K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

4.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.

Authors:  G Poli; J M Orenstein; A Kinter; T M Folks; A S Fauci
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

5.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

6.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

7.  Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.

Authors:  Juan García-Arriaza; Pilar Arnáez; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

8.  Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.

Authors:  Maura Manion; Benigno Rodriguez; Kathleen Medvik; Gareth Hardy; Clifford V Harding; Robert T Schooley; Richard Pollard; David Asmuth; Robert Murphy; Edward Barker; Kirsten E Brady; Alan Landay; Nick Funderburg; Scott F Sieg; Michael M Lederman
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

9.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

10.  Expression profile of host restriction factors in HIV-1 elite controllers.

Authors:  Mohamed Abdel-Mohsen; Rui André Saraiva Raposo; Xutao Deng; Manqing Li; Teri Liegler; Elizabeth Sinclair; Mohamed S Salama; Hussam El-Din A Ghanem; Rebecca Hoh; Joseph K Wong; Michael David; Douglas F Nixon; Steven G Deeks; Satish K Pillai
Journal:  Retrovirology       Date:  2013-10-16       Impact factor: 4.602

View more
  18 in total

1.  Dynamic Modulation of Expression of Lentiviral Restriction Factors in Primary CD4+ T Cells following Simian Immunodeficiency Virus Infection.

Authors:  Andrew R Rahmberg; Premeela A Rajakumar; James M Billingsley; R Paul Johnson
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

2.  Antiviral gene expression in psoriasis.

Authors:  R A Raposo; R Gupta; M Abdel-Mohsen; M Dimon; M Debbaneh; W Jiang; V A York; K S Leadabrand; G Brown; M Malakouti; S Arron; P J Kuebler; J J Wu; S K Pillai; D F Nixon; W Liao
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-03-23       Impact factor: 6.166

3.  Select host restriction factors are associated with HIV persistence during antiretroviral therapy.

Authors:  Mohamed Abdel-Mohsen; Charlene Wang; Matthew C Strain; Steven M Lada; Xutao Deng; Leslie R Cockerham; Christopher D Pilcher; Frederick M Hecht; Teri Liegler; Douglas D Richman; Steven G Deeks; Satish K Pillai
Journal:  AIDS       Date:  2015-02-20       Impact factor: 4.177

4.  Dynamic regulation of host restriction factor expression over the course of HIV-1 infection in vivo.

Authors:  Rui André Saraiva Raposo; Mohamed Abdel-Mohsen; Xutao Deng; Frederick M Hecht; Christopher D Pilcher; Satish K Pillai; Douglas F Nixon
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

5.  Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.

Authors:  Kerry J Lavender; Kathrin Gibbert; Karin E Peterson; Erik Van Dis; Sandra Francois; Tyson Woods; Ronald J Messer; Ali Gawanbacht; Janis A Müller; Jan Münch; Katie Phillips; Brent Race; Michael S Harper; Kejun Guo; Eric J Lee; Mirko Trilling; Hartmut Hengel; Jacob Piehler; Jens Verheyen; Cara C Wilson; Mario L Santiago; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

6.  Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo.

Authors:  Bradley S Barrett; Kejun Guo; Michael S Harper; Sam X Li; Karl J Heilman; Nicholas O Davidson; Mario L Santiago
Journal:  Virology       Date:  2014-10-07       Impact factor: 3.616

7.  Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Authors:  Line Vibholm; Mariane H Schleimann; Jesper F Højen; Thomas Benfield; Rasmus Offersen; Katrine Rasmussen; Rikke Olesen; Anders Dige; Jørgen Agnholt; Judith Grau; Maria Buzon; Burghardt Wittig; Mathias Lichterfeld; Andreas Munk Petersen; Xutao Deng; Mohamed Abdel-Mohsen; Satish K Pillai; Sofie Rutsaert; Wim Trypsteen; Ward De Spiegelaere; Linos Vandekerchove; Lars Østergaard; Thomas A Rasmussen; Paul W Denton; Martin Tolstrup; Ole S Søgaard
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

8.  Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo.

Authors:  Mohamed Abdel-Mohsen; Xutao Deng; Ali Danesh; Teri Liegler; Evan S Jacobs; Andri Rauch; Bruno Ledergerber; Philip J Norris; Huldrych F Günthard; Joseph K Wong; Satish K Pillai
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

9.  CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.

Authors:  Hassen Kared; Sahar Saeed; Marina B Klein; Naglaa H Shoukry
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

10.  Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms.

Authors:  Michael S Harper; Kejun Guo; Kathrin Gibbert; Eric J Lee; Stephanie M Dillon; Bradley S Barrett; Martin D McCarter; Kim J Hasenkrug; Ulf Dittmer; Cara C Wilson; Mario L Santiago
Journal:  PLoS Pathog       Date:  2015-11-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.